Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab

Clinical Genitourinary Cancer- United States

doi 10.1016/j.clgc.2016.12.019

Full Text

Abstract

Available in

Categories

Date

June 1, 2017

Authors

Publisher

Elsevier BV

Related search

Salvage Ipilimumab Associated With a Significant Response in Sarcomatoid Renal Cell Carcinoma

Journal for ImmunoTherapy of Cancer

Molecular Medicine

Cancer Research

English

Complete Remission of Bone Metastases in Renal Cell Carcinoma With Nivolumab

English

Nivolumab in Treatment of Renal Cell Carcinoma During Renal Replacement Therapy

Oncology in Clinical Practice

English

Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma

European Urology

English

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Clinical Cancer Research

Cancer Research

English

Nivolumab in the Treatment of Advanced Renal Cell Carcinoma

Oncology in Clinical Practice

English

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma

Frontiers in Oncology

Cancer Research

English

Pd57-06 Altered Immune Cell Repertoire and Activity After Checkpoint Blockade Immunotherapy With Nivolumab in Renal Cell Carcinoma

Journal of Urology

English

Molecular Markers Associated With the Response to Therapy With Everolimus in Patients With Renal Cell Carcinoma

Siberian Journal of Oncology

Cancer Research

English